Drug Profile
Research programme: ultra-concentrated insulin - Arecor/JDRF
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator JDRF
- Developer Arecor; JDRF
- Class Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral)
- 28 Jul 2016 Arecor has patent protection for ArestatTM platform technologies (Arecor website, July 2016)
- 25 Jul 2016 Arecor and JDRF agree to co-develop ultra-concentrated insulin in USA for Type-1 diabetes